David R. Harper
Profile
Dr. David R.
Harper is Chief Scientific Officer at AmpliPhi Biosciences Corp.
Dr. Harper was previously employed as Chief Scientific Officer by Biocontrol Ltd.
He received his undergraduate degree from the University of Warwick and a doctorate degree from the University of Newcastle-upon-Tyne.
Former positions of David R. Harper
Companies | Position | End |
---|---|---|
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Biocontrol Ltd. (United Kingdom)
Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Founder | - |
Training of David R. Harper
University of Warwick | Undergraduate Degree |
Newcastle University | Doctorate Degree |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Biocontrol Ltd. (United Kingdom)
Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- David R. Harper